Jon Cousin

Cooley advised Secura Bio on intellectual property diligence matters surrounding its acquisition of global rights to Farydak from Novartis. Farydak is a prescription medication used to treat patients who have received prior treatment for multiple myeloma, a cancer that forms malignant plasma cells in the bone marrow.

“We are very pleased to acquire worldwide rights to Farydak as we execute our plan to aggressively build a meaningful, worldwide oncology portfolio,” said Joseph M. Limber, president and CEO at Secura Bio. “Farydak will be a critical cornerstone of our strategy, as it offers a potentially valuable and high-growth treatment option for physicians in their therapeutic regimen for multiple myeloma patients when combined with a variety of other multiple myeloma therapies.”

Cooley advised Secura Bio on intellectual property diligence matters surrounding its $311 million acquisition ($70 million upfront and $241 million in milestones) of global rights to Copiktra. Copiktra is a prescription oncology medication used to treat patients who have received prior treatment for certain types of cancer, such as chronic lymphocytic leukemia and small lymphocytic lymphoma.

“Completing the Copiktra acquisition represents a major step in building our worldwide oncology portfolio,” said Joseph M. Limber, president and CEO at Secura Bio.

Cooley advised global investment firm Sixth Street on its strategic investment in Blueprint Medicines, a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Lawyers Mischi a Marca, Matt Browne, Matt Scarano, Addison Pierce, Matt Kong and Nick Neuteufel led the Cooley team advising Sixth Street. 

Cooley advised Rodeo Therapeutics, a biopharmaceutical company that develops small molecule therapies, on its agreement to sell to Amgen, a leader in biotechnology-based human therapeutics, for $721 million. Partner Laura Medina led the Cooley team advising Rodeo. 

Read more

Jazz Pharmaceuticals in its acquisition of Redx Pharma's (Redx) pan-RAF inhibitor program for the potential treatment of RAF and RAS mutant tumors. Redx will perform certain pre-clinical activities for the program under a separate collaboration agreement with Jazz. Jazz will be responsible for further development, regulatory activities and commercialization. Jazz will pay Redx an upfront payment of $3.5 million. Redx is eligible to receive up to $203 million in development, regulatory and commercial milestone payments and incremental tiered royalties in mid-single digit percentage, based on any future net sales.